Clinical Trial Update: Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative Colitis [Phase 3]

View source ↗

Summary

An update on a Phase 3 trial assessing the efficacy and safety of adalimumab for inducing clinical response in ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Clalit Health Services | Conditions: Ulcerative Colitis | Phase 3 | Status: UNKNOWN